OptimizeRx (NASDAQ:OPRX) Given “Buy” Rating at Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a report published on Thursday morning,Benzinga reports. Roth Mkm currently has a $16.00 price objective on the stock, down from their previous price objective of $20.00.

Several other research firms also recently commented on OPRX. Barclays decreased their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday. JMP Securities lowered their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday. B. Riley began coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They issued a “buy” rating and a $18.50 price target for the company. Stifel Nicolaus decreased their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Royal Bank of Canada dropped their target price on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, August 16th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.42.

OptimizeRx Price Performance

Shares of OptimizeRx stock opened at $3.83 on Thursday. The company has a quick ratio of 3.07, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock’s fifty day moving average is $6.60 and its 200 day moving average is $8.98. OptimizeRx has a one year low of $3.78 and a one year high of $16.65.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently bought and sold shares of the stock. Summit Securities Group LLC purchased a new stake in OptimizeRx in the 2nd quarter worth $25,000. BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Quest Partners LLC lifted its position in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares in the last quarter. Connors Investor Services Inc. lifted its position in shares of OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares in the last quarter. Finally, Barclays PLC boosted its stake in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares during the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.